• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)

    2/12/24 7:11:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGMO alert in real time by email
    SC 13G/A 1 d662582dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    SANGAMO THERAPEUTICS, INC.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    800677106

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 800677106

     

     1.   

     Names of Reporting Persons.

     

     Biogen Inc. 33-0112644

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

       6.  

     Shared Voting Power

     

     14,652,466

       7.  

     Sole Dispositive Power

     

       8.  

     Shared Dispositive Power

     

     14,652,466

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     14,652,466 shares

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)1

     

     8.26%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO


    CUSIP No. 800677106

     

     1.   

     Names of Reporting Persons.

     

     Biogen MA Inc.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     MASSACHUSETTS

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

       6.  

     Shared Voting Power

     

     14,652,466

       7.  

     Sole Dispositive Power

     

       8.  

     Shared Dispositive Power

     

     14,652,466

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     14,652,466 shares

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)1

     

     8.26%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    The percent ownership is calculated based upon an aggregate of 177,346,980 shares of common stock outstanding as of October 30, 2023, as reported in the Sangamo Therapeutics, Inc. Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 1, 2023.


    AMENDMENT NO. 1 TO SCHEDULE 13G

    Reference is hereby made to the statement on Schedule 13G relating to the Common Stock of the Issuer filed with the Securities and Exchange Commission by the Reporting Persons on April 17, 2020 (the “Schedule 13G”). Terms defined in the Schedule 13G are used herein as so defined.

    The following items of the Schedule 13G are hereby amended and restated as follows:

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of cover page.

     

      (b)

    Percent of class:

    See Row 11 of cover page.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    See Row 5 of cover page.

     

      (ii)

    Shared power to vote or to direct the vote:

    See Row 6 of cover page.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class.

    Not applicable


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

    BIOGEN INC.
    By:   /s/ Michael Dambach
      Name: Michael Dambach
      Title: Treasurer
    BIOGEN MA INC.
    By:   /s/ Michael Dambach
      Michael Dambach
      Treasurer

    Date: February 12, 2024

    Get the next $SGMO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SGMO

    DatePrice TargetRatingAnalyst
    11/7/2025$1.00Overweight → Equal Weight
    Barclays
    12/13/2024$7.00Hold → Buy
    Truist
    12/10/2024$10.00Buy
    H.C. Wainwright
    11/3/2023$6.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    4/28/2023$5.00 → $1.50Neutral → Underperform
    BofA Securities
    2/27/2023$16.00Neutral → Outperform
    Wedbush
    1/6/2023$8.00 → $5.00Buy → Neutral
    BofA Securities
    6/13/2022$5.00Neutral
    Wedbush
    More analyst ratings

    $SGMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

    RICHMOND, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company today announced that the company has scheduled the release of its first quarter 2026 financial results after the market closes on Thursday, May 14, 2026. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, May 14, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participant

    5/11/26 4:05:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

    RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format. Presentations will highlight the progression of Sangamo's neurology pipeline, including advances in zinc finger epigenetic regulation and developments in modular integrase technology. "ASGCT is an important forum for showcasing innovation in gene and cell therapy, and we look forward to presenting advances in our neurology pipeline,

    4/30/26 8:05:00 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

    RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq Capital Market to the OTCQB Venture Market on Tuesday, May 5, 2026. This transition follows the receipt by Sangamo of a notice from The Nasdaq Stock Market LLC indicating that Sangamo's common stock will be delisted from the Nasdaq Capital Market due to non-compliance with Nasdaq's minimum bid price requirement. Sangamo intends to request a hearing from Nasdaq to appeal the delisting determination. The hearing will not stay the suspension of trading of Sangamo's common stock, and trading o

    4/29/26 8:05:00 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sangamo Therapeutics downgraded by Barclays with a new price target

    Barclays downgraded Sangamo Therapeutics from Overweight to Equal Weight and set a new price target of $1.00

    11/7/25 8:28:38 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics upgraded by Truist with a new price target

    Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00

    12/13/24 8:18:20 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright reiterated coverage on Sangamo Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00

    12/10/24 11:58:57 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $SGMO
    SEC Filings

    View All

    Principal Accounting Officer Jain Nikunj covered exercise/tax liability with 1,919 shares, decreasing direct ownership by 0.81% to 235,292 units (SEC Form 4) (for withholding tax)

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    5/27/26 7:30:12 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Head of Research & Technology Davis Gregory D covered exercise/tax liability with 1,630 shares, decreasing direct ownership by 1% to 113,654 units (SEC Form 4) to cover withholding tax

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    5/27/26 7:30:14 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 4,036 shares, decreasing direct ownership by 1% to 328,733 units (SEC Form 4) (for withholding tax)

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    5/27/26 7:30:09 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Sangamo Therapeutics Inc.

    10-Q - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

    5/14/26 4:03:39 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

    5/14/26 4:02:06 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 10-K/A filed by Sangamo Therapeutics Inc.

    10-K/A - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

    4/29/26 7:34:49 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Leadership Updates

    Live Leadership Updates

    View All

    Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm

    5/16/23 8:00:00 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

    CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio

    11/22/21 7:00:00 AM ET
    $ORGO
    $PACB
    $SGMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa

    5/24/21 4:15:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Financials

    Live finance-specific insights

    View All

    Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

    RICHMOND, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company today announced that the company has scheduled the release of its first quarter 2026 financial results after the market closes on Thursday, May 14, 2026. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, May 14, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participant

    5/11/26 4:05:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

    Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in study, which U.S. Food and Drug Administration (FDA) reiterated in October may serve as primary basis of approval under Accelerated Approval pathway Rolling submission of Biologics License Agreement (BLA) to FDA seeking ST-920 approval is in progress Transitioned to a clinical-stage neurology company with six clinical sites activated in Phase 1/2 STAND study in chronic neuropathic pain Announced in April, third neurology capsid license agreement, this time with Eli

    3/30/26 4:01:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

    RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2025 financial results after the market closes on Monday, March 30, 2026. The company will hold a conference call at 4:30 p.m. Eastern on Monday, March 30, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participa

    3/19/26 4:03:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

    11/12/24 4:53:35 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

    11/4/24 1:54:32 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

    8/16/24 6:40:25 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care